INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Nov 02, 2015 |
Director, President and CSO
Trans History: 628
|
Director, President and CSO | Form 4 | Bona fide gift | 43,348 | -- | 500,000 |
| Dec 16, 2014 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Bona fide gift | 3,264 | -- | 500,000 |
| Aug 28, 2014 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Bona fide gift | 294 | -- | 500,000 |
| Feb 13, 2014 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Bona fide gift | 568,343 | -- | 500,000 |
| Aug 27, 2014 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 310 | $351.33 | 500,294 |
| Aug 27, 2014 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 5,116 | $351.33 | 500,604 |
| Dec 14, 2017 |
Director, President and CSO
Trans History: 628
|
Director, President and CSO | Form 4 | Bona fide gift | 89,264 | -- | 500,847 |
| Dec 02, 2015 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 1,101 | $554.58 | 501,900 |
| Dec 16, 2015 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 1,921 | $52.03 | 501,921 |
| Dec 02, 2015 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 1,600 | $553.32 | 503,001 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.